Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine

Brain Research

Volumn 1203, Issue , 2008, Pages 68-78

  Rahman, Zia ^a   Ring, Robert H ^a   Young, Kimberly ^a   Platt, Brian ^a   Lin, Qian ^a   Schechter, Lee E ^a   Rosenzweig Lipson, Sharon ^a   Beyer, Chad E ^a  

^a PFIZER INC   (United States)

Author keywords

Antidepressants; Microdialysis; Norepinephrine; Normetanephrine; OCT3; Venlafaxine

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ANTIDEPRESSANT AGENT; BRAIN MONOAMINE; DESIPRAMINE; DOPAMINE; NORADRENALIN; NORADRENALIN TRANSPORTER; NORMETADRENALIN; SEROTONIN; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXTRACELLULAR FLUID; FRONTAL LOBE; HINDLIMB SUSPENSION; IMMOBILITY RESPONSE, TONIC; MALE; MICRODIALYSIS; NOREPINEPHRINE; NORMETANEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

RATTUS;

EID: 41249103934     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.01.062     Document Type: Article

References (52)

1. Amara S.G., and Kuhar M.J. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16 (1993) 73-93
2. Amphoux A., Vialou V., Drescher E., Bruss M., Mannoury La Cour C., Rochat C., Millan M.J., Giros B., Bonisch H., and Gautron S. Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50 (2006) 941-952
3. Aoyama N., Takahashi N., Kitaichi K., Ishihara R., Saito S., Maeno N., Ji X., Takagi K., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Iwata N., Inada T., and Ozaki N. Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin. Exp. Res. 30 (2006) 1644-1649
4. Axelrod J. Biochemical pharmacology of catecholamines and its clinical implications. Trans. Am. Neurol. Ass. 96 (1971) 179-186
5. Barker E.L., and Blakely R.D. Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: the Forth Generation of Progress (1995), Raven, New York 321-333
6. Beyer C.E., Boikess S., Luo B., and Dawson L.A. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J. Psychopharmacol. 16 (2002) 297-304
7. Blakely R.D., De Felice L.J., and Hartzell H.C. Molecular physiology of norepinephrine and serotonin transporters. J. Exp. Biol. 196 (1994) 263-281
8. Blier P., and De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15 (1994) 220-226
9. Burgen Asv I.L. The inhibition of noradrenaline uptake by sympathomimetic amines in the rat isolated heart. Br. J. Pharmacol. 25 (1965) 34-49
10. Callingham B.A., and Burgen A.S. The uptake of isoprenaline and noradrenaline by the perfused rat heart. Mol. Pharmacol. 2 (1966) 37-42
11. Cryan J.F., Mombereau C., and Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 29 (2005) 571-625
12. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol. Ther. 91 (2001) 35-62
13. Feng N., Mo B., Johnson P.L., Orchinik M., Lowry C.A., and Renner K.J. Local inhibition of organic cation transporters increases extracellular serotonin in the medial hypothalamus. Brain Res. 1063 (2005) 69-76
14. Frazer A. Pharmacology of antidepressants. J. Clin. Psychopharmacol. 17 Suppl. 1 (1997) 2S-18S
15. Glowinski J., Snyder S.H., and Axelrod J. Subcellular localization of H3-norepinephrine in the rat brain and the effect of drugs. J. Pharmacol. Exp. Ther. 152 (1966) 282-292
16. Goldstein D.S., Eisenhofer G., and Kopin I.J. Sources and significance of plasma levels of catechols and their metabolites in humans. J. Pharmacol. Exp. Ther. 305 (2003) 800-811
17. Graefe K.H., and Henseling M. Neuronal and extraneuronal uptake and metabolism of catecholamines. Gen. Pharmacol. 14 (1983) 27-33
18. Grundemann D., Schechinger B., Rappold G.A., and Schomig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat. Neurosci. 1 (1998) 349-351
19. Haag C., Berkels R., Grundemann D., Lazar A., Taubert D., and Schomig E. The localisation of the extraneuronal monoamine transporter (EMT) in rat brain. J. Neurochem. 88 (2004) 291-297
20. Hayer-Zillgen M., Bruss M., and Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol. 136 (2002) 829-836
21. Hendley E.D., Taylor K.M., and Snyder S.H. 3H-normetanephrine uptake in rat brain slices. Relationship to extraneuronal accumulation of norepinephrine. Eur. J. Pharmacol. 12 (1970) 167-179
22. Heninger G.R., Delgado P.L., and Charney D.S. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 29 (1996) 2-11
23. Iversen L.L. The uptake of adrenaline by the rat isolated heart. Br. J. Pharmacol. Chemother. 24 (1965) 387-394
24. Jonker J.W., and Schinkel A.H. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther. 308 (2004) 2-9
25. Kekuda R., Prasad P.D., Wu X., Wang H., Fei Y.J., Leibach F.H., and Ganapathy V. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J. Biol. Chem. 273 (1998) 15971-15979
26. Kitaichi K., Fukuda M., Nakayama H., Aoyama N., Ito Y., Fujimoto Y., Takagi K., Takagi K., and Hasegawa T. Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice. Neurosci. Lett. 382 (2005) 195-200
27. Koch S., Hemrick-luecke S.K., Thompson L.K., Evans D.C., Threlkeld P.G., Nelson D.L., Perry K.W., and Bymaster F.P. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45 (2003) 935-944
28. Koepsell H. Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol. Sci. 25 (2004) 375-381
29. Koepsell H., Schmitt B.M., and Gorboulev V. Organic cation transporters. Rev. Physiol. Biochem. Pharmacol. 150 (2003) 36-90
30. Kopin I.J. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol. Rev. 37 (1985) 333-364
31. Lazar A., Grundemann D., Berkels R., Taubert D., Zimmermann T., and Schomig E. Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3). J. Hum. Genet. 48 (2003) 226-230
32. Lazar A., Walitza S., Jetter A., Gerlach M., Warnke A., Herpertz-dahlmann B., Grundemann D., Grimberg G., Schulz E., Remschmidt H., Wewetzer C., and Schomig E. Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. (2007) 1-14
33. Maas J.W., Koslow S.H., Davis J., Katz M., Frazer A., Bowden C.L., Berman N., Gibbons R., Stokes P., and Landis D.H. Catecholamine metabolism and disposition in healthy and depressed subjects. Arch. Gen. Psychiatry 44 (1987) 337-344
34. Martel F., and Azevedo I. An update on the extraneuronal monoamine transporter (EMT): characteristics, distribution and regulation. Curr. Drug Metab. 4 (2003) 313-318
35. Martel F., Ribeiro L., Calhau C., and Azevedo I. Comparison between uptake2 and rOCT1: effects of catecholamines, metanephrines and corticosterone. Naunyn-Schmiedeberg's Arch. Pharmacol. 359 (1999) 303-309
36. O'Leary O.F., Bechtholt A.J., Crowley J.J., Hill T.E., Page M.E., and Lucki I. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology (Berl) 192 (2007) 357-371
37. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, New York
38. Potter W.Z., and Manji H.K. Catecholamines in depression: an update. Clin. Chem. 40 (1994) 279-287
39. Redrobe J.P., Bourin M., Colombel M.C., and Baker G.B. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berl) 138 (1998) 1-8
40. Rosenzweig-Lipson S., Beyer C.E., Hughes Z.A., Khawaja X., Rajarao S.J., Malberg J.E., Rahman Z., Ring R.H., and Schechter L.E. Differentiating antidepressants of the future: efficacy and safety. Pharmacol. Ther. 113 (2007) 134-153
41. Russ H., Staust K., Martel F., Gliese M., and Schomig E. The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia. Eur. J. Neurosci. 8 (1996) 1256-1264
42. Schanberg S.M., Schildkraut J.J., Breese G.R., and Kopin I.J. Metabolism of normetanephrine-H3 in rat brain-identification of conjugated 3-methoxy-4-hydrophenylglycol as the major metabolite. Biochem. Pharmacol. 17 (1968) 247-254
43. Schildkraut J.J., and Mooney J.J. Toward a rapidly acting antidepressant: the normetanephrine and extraneuronal monoamine transporter (uptake 2) hypothesis. Am. J. Psychiatry 161 (2004) 909-911
44. Schildkraut J.J., Green R., Gordon E.K., and Durell J. Normetanephrine excretion and affective state in depressed patients treated with imipramine. Am. J. Psychiatry 123 (1966) 690-700
45. Schildkraut J.J., Dodge G.A., and Logue M.A. Preliminary findings on the effects of amitriptyline on norepinephrine-H3 metabolism in rat brain. Dis. Nerv. Syst. 30 (1969) 44-46 (Suppl)
46. Schildkraut J.J., Winokur A., Draskoczy P.R., and Hensle J.H. Changes in norepinephrine turnover in rat brain during chronic administration of imipramine and protriptyline: a possible explanation for the delay in onset of clinical antidepressant effects. Am. J. Psychiatry 127 (1971) 1032-1039
47. Stahl S.M., Grady M.M., Moret C., and Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 10 (2005) 732-747
48. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85 (1985) 367-370
49. Trendelenburg U. The TiPS lecture: functional aspects of the neuronal uptake of noradrenaline. Trends Pharmacol. Sci. 12 (1991) 334-337
50. Vialou V., Amphoux A., Zwart R., Giros B., and Gautron S. Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J. Neurosci. 24 (2004) 2846-2851
51. Wilson V.G., Grohmann M., and Trendelenburg U. The uptake and O-methylation of 3H-(+/-)-isoprenaline in rat cerebral cortex slices. Naunyn-Schmiedeberg's Arch. Pharmacol. 337 (1988) 397-405
52. Wu X., Kekuda R., Huang W., Fei Y.J., Leibach F.H., Chen J., Conway S.J., and Ganapathy V. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J. Biol. Chem. 273 (1998) 32776-32786